Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma

被引：0

作者：

Xin Li

Xinyu Su

Chen Yan

Yuanyuan Ma

Heng Li

Jianhong Xia

Hongliang Li

Qian Jiang

Liqing Zhou

Zhengyun Zou

机构：

[1] Huai’an Hospital Affiliated to Xuzhou Medical University,Department of Radiation Oncology

[2] Medical School of Nanjing University,Department of Radiation Oncology, The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Drum Tower Hospital

[3] Clinical College of Nanjing Medical University,Department of Radiation Oncology, The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital

[4] Clinical College of Nanjing University of Chinese Medicine,Department of Radiation Oncology, The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Esophageal carcinoma; Vascular endothelial growth factor; Radiotherapy; Curative effect; Anti-angiogenesis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Vascular endothelial growth factor (VEGF) is related to the radiation resistance of tumors, resulting in the failure of tumor radiotherapy. The purpose of this study was to discuss the role of VEGF in radiotherapy resistance of esophageal squamous cell carcinoma (ESCC). We used the VEGF kit by ELISA to detect the serum VEGF level of ESCC patients who only received radiotherapy. The expression of VEGF in ESCC cells after siRNA treatment was verified by Western blot. The sensitivity of ESCC cells to radiation after knocking down VEGF was analyzed by Clonogenic assay and Cell counting kit (CCK-8). The results showed that the level of serum VEGF in patients with ESCC before and after radiotherapy was related to the clinical response, and it was confirmed that knocking down the expression of VEGF in ESCC cells improved the sensitivity to radiation.

引用

页码：2543 / 2550

页数：7

共 228 条

[21]

Zhu X(2019)Cancer treatment and survivorship statistics, 2019 CA Cancer J Clin 69 995-undefined

[22]

Cummings D(2003)Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches Ann Surg 238 519-undefined

[23]

Wong J(2019)Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy J Hematol Oncol 12 209-undefined

[24]

Palm R(2021)Continuous low-dose apatinib combined with WBRT significantly reduces peritumoral edema and enhances the efficacy of symptomatic multiple brain metastases in NSCLC Technol Cancer Res Treat 20 1182-undefined

[25]

Hoffe S(2020)Anlotinib combined with chemoradiotherapy exhibits significant therapeutic efficacy in esophageal squamous cell carcinoma Front Oncol 10 145-undefined

[26]

Almhanna K(2017)Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer Cancer Invest 35 8136-undefined

[27]

Vignesh S(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 293-undefined

[28]

Dong D(2020)Silencing vascular endothelial growth factor C increases the radiosensitivity in nasopharyngeal carcinoma CNE-2 cells J Cell Biochem 121 14503-undefined

[29]

Yan Fu(2004)Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 undefined-undefined

[30]

Chen F(2005)Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18] J Clin Oncol 23 undefined-undefined

← 1 2 3 4 5 6 7 8 9 10 →